MedTrace Logo

Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in Asthma

NCT03137784 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 148

Last updated 2019-01-16

Study results available
· View outcomes & findings →

Summary

The purpose of this trial is to characterize the bronchodilator effects and safety of 25 ug and 50 ug o.d. NVA237 (glycopyrronium bromide) doses compared to placebo in asthma patients

Conditions

Interventions

DRUG

NVA237 (glycopyrronium bromide)

In each treatment arm, patient will receive NVA237 (glycopyrronium bromide) 25 ug and 50 ug dose

DRUG

Placebo

In each treatment arm, patient will receive placebo

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-04
Primary Completion
2017-12-29
Completion
2017-12-29
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Germany
  • Japan
  • Latvia
  • Lithuania

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03137784 on ClinicalTrials.gov